Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab Monotherapy After Chemoradiotherapy for Residual Cervical Cancer
ChiCTR2500113692Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Guangzhou Medical University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of iparomlimab and tuvonralimab in Cervical Cancer (CC), sponsored by Affiliated Cancer Hospital of Guangzhou Medical University. Primary endpoint: Complete tumor response rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
iparomlimabtuvonralimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2500113692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113692.